🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06076226
Recruiting

A Retrospective Study on the Relationship Between Donor Leukocyte Telomere Length and Prognosis of Acute Leukemia Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation

NCT06076226 · tracked via the Priya Life Science China tracker
Sponsor
Zhejiang University
Phase
Started
2015-01-01
Last updated
2023-10-10

Condition(s) studied

Acute Leukemia

Investigational drug(s) / intervention(s)

No intervention, observation study

No intervention, observation study: No intervention, observation study

Study summary

This post hoc analysis included patients with acute leukemia who underwent allo-HSCT at the First Affiliated Hospital of Zhejiang University School of Medicine and Ruijin Hospital Shanghai Jiaotong University School of Medicine. Patients and their donors were assessed for eligibility to join this study. The inclusion criteria were: (1) age ≥ 5 years; (2) diagnosis of acute leukemia including acute myeloid leukemia, acute lymphocytic leukemia, and mixed phenotype acute leukemia; (3) patients attained complete remission (CR) and achieved full engraftment with 100% donor chimerism following allo-HSCT; (4) telomere testing was conducted on peripheral leukocytes of donors before granulocyte colony-stimulating factor (G-CSF) mobilization, and the results were obtained. Written informed consent was obtained from all included patients and their donors, and the study was conducted in compliance with the Declaration of Helsinki. Ethical approval was approved by the ethics review committee of the First Affiliated Hospital of Zhejiang University School of Medicine.

Eligibility

Sex
ALL
Min age
5 Years
Max age
90 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age ≥ 5 years * First allo-HSCT from matched related, unrelated, or haploidentical donors * Achievement of complete remission after allo-HSCT * Donor blood sample collection before granulocyte colony-stimulating factor mobilization Exclusion Criteria * Non-acute leukemia diagnoses, including acute myeloid leukemia, acute lymphocytic leukemia, and mixed phenotype acute leukemia * Failure to achieve engraftment with full donor chimerism after allo-HSCT * Inability to extract DNA for telomere length analysis.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Clinical research ethics committee of the first affiliated hospital, college of medicine, zhejiang University Hangzhou Zhejiang Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06076226 on ClinicalTrials.gov ↗ ← All trials in China